Print Friendly Page

Protocol No. UW17088

Principal Investigator Maloney, James

Phase N/A

Age Group Adult

Scope Local

Sponsor Type Industry

Title Blood-Based Biomarkers for Minimal Residual Disease Monitoring in Patients Undergoing Surgical Resection for the Treatment of Lung Cancer

Objective The purpose of this research study is to determine if a blood test can be developed to detect cancer cells that are leftover in the body or that may come back after having treatment. We are doing this research because we think a blood test has the potential to be more accurate than a chest x-ray or a CT scan in detecting lung cancer. In addition, providing a blood sample is a common medical procedure that is less invasive and has a lower risk of side effects than the chest x-rays or CT scans currently used to check for lung cancer. A more accurate, less risky test to detect cancer cells could also lead to earlier detection and treatment of lung cancer

Treatment NA

Description Blood‐based biomarkers for minimal residual disease monitoring in patients undergoing curative intent therapy for the treatment of lung cancer

Key Eligibility
  • Subject has recent (within 6 months of enrollment) untreated pathologic diagnosis of primary lung cancer or radiographic imaging with characteristics that are high risk for malignancy without biopsy
  • Subject scheduled to proceed for curative intent therapy such as radiation or surgery
  • Hematocrit level of greater than or equal to 32
  • Subject is male or female, 18 years and older
  • Neoadjuvant therapy prior to enrollment
  • Known cancer diagnosis within the past 5 years (with the exceptions of basal cell or squamous cell skin cancers)
  • Subjects diagnosed with mesothelioma

  • Applicable Disease Sites Lung

    Status Open

    Participating Institutions UW Hospital and Clinics